Compatibility «Candizole» and «Glyxambi»

• Interactions Candizole with Glyxambi

  • Negative interactions
    • ⓘ Co-administration with rifampicin reduced the effectiveness of linagliptin by 40%, which indicates the possibility of reducing the effectiveness of linagliptin in the case of its combination with active P-gp inducers or cytochrome P450 CYP3A4 isoenzymes, especially if these drugs are used for a long time.
    • ⓘ Linagliptin is a weak competitive inhibitor of the CYP3A4 isoenzyme.
    • ⓘ This indicates that linagliptin in vivo'>in vivo is not an inhibitor of metabolism mediated by the CYP2C8 isoenzyme, and confirms the conclusion that there is no significant inhibitory effect of linagliptin in vivo'>in vivo on the CYP3A4 isoenzyme.
    • ⓘ The combined use of linagliptin (a single dose of 5 mg orally) and ritonavir (multiple doses of 200 mg orally), an active P-gp inhibitor and CYP3A4 isoenzyme, increased the values of AUC and C_max linagliptin by about 2 and 3 times, respectively.
    • ⓘ Therefore, clinically significant interaction with other inhibitors of P-gp and CYP3A4 isoenzyme is not expected and dose adjustment is not required.
    • ⓘ Repeated co-administration of linagliptin and rifampicin, an active inducer of P-gp and the CYP3A4 isoenzyme, led to a decrease in the AUC and C_max of linagliptin by 39.6 and 43.8%, respectively, and a decrease in inhibition of the basal activity of DPP-4 by about 30%.
    • ⓘ Dose changes while taking drugs that are metabolized with the participation of the CYP3A4 isoenzyme are considered inappropriate.
  • No interactions
    • ⓘ Co-administration with other active inducers of P-gp or CYP3A4, such as carbamazepine, phenobarbital and phenytoin, has not been studied.
    • ⓘ Linagliptin does not have a clinically significant effect on the pharmacokinetics of metformin, glibenclamide, simvastatin, pioglitazone, warfarin, digoxin and oral contraceptive drugs, which has been proven in vivo and is based on the low ability of linagliptin to interact with substrates of CYP3A4, CYP2C9, CYP2C8, P-gp isoenzymes and organic transporter molecules cations.
    • ⓘ The combined use of several doses of linagliptin 10 mg per day (above the therapeutic dose) and pioglitazone 45 mg per day (multiple doses), which is a substrate for CYP2C8 and CYP3A4 isoenzymes, did not have a clinically significant effect on the pharmacokinetics of linagliptin or pioglitazone, or the active metabolites of pioglitazone.
  • Unclear interactions
    • ⓘ P-gp inducers or CYP3A4 isoenzymes.
    • ⓘ Linagliptin, used repeatedly in healthy volunteers at a dose of 10 mg per day (above the therapeutic dose), had minimal effect on the pharmacokinetic parameters of simvastatin, which is a sensitive substrate for CYP3A4.

Decoding the colors of interactions and contraindications

Dangerous	—	a pronounced negative interaction or contraindication.
Negative	—	negative interaction or side effect that may reduce effectiveness.
Positive	—	the interaction can SOMETIMES be used as a positive (often a dose adjustment is needed), or it is an indication.
No	—	the drugs do NOT interact, which is separately indicated in the instructions.
Unclear	—	the system failed to pre-assess the danger.

Video instruction

▶

Look at ▶Youtube

Additional information

• Kiberis checks interactions and evaluates drug compatibility for free online right in the instructions thanks to the latest artificial intelligence technologies. The accuracy of finding is more than 95%, the accuracy of the hazard assessment is more than 80%. The online medical service takes into account all the drug groups of the selected drugs and all their components. And since the database contains 25,000 drugs with detailed instructions, not every pharmacologist can compete with our artificial intelligence. List of popular interactions.
• Why do I need to
  • Avoid dangerous prescriptions for your patients.
  • Check the contraindications.
  • Evaluate the safety of therapy in the treatment of children.
  • See the compatibility of drugs with alcohol (enter it as a drug).
  • Point the doctor to the found interaction - you may need to adjust the therapy.
  • Do you need an API for interactions/drug analogues for your project? Write to us.
• The use of information about interactions is only possible as an introduction. This information should not be used to adjust therapy without consulting a specialist.
• The article is written: artificial intelligence Kiberis
• Sources: official instructions for medicines and their active substances, as well as inter-group interactions described in medical studies and textbooks.
• Total analyzed: 170,037,924 possible combinations of drugs and their components were found 412,574 interacting combinations.
• Medicine section: Standard evidence-based medicine
• The date of the last update of the interaction database: 2026-05-07

Category - medicine